esomeprazole magnesium (oral medication)
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Erosive Esophagitis
Conditions
Erosive Esophagitis, Reflux Esophagitis, Gastroesophageal Reflux Disease
Trial Timeline
Jun 1, 2004 → Aug 1, 2005
NCT ID
NCT00206180About esomeprazole magnesium (oral medication)
esomeprazole magnesium (oral medication) is a approved stage product being developed by AstraZeneca for Erosive Esophagitis. The current trial status is completed. This product is registered under clinical trial identifier NCT00206180. Target conditions include Erosive Esophagitis, Reflux Esophagitis, Gastroesophageal Reflux Disease.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00206180 | Approved | Completed |
Competing Products
20 competing products in Erosive Esophagitis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| YH1885L(Revaprazan) + Esomeprazole 20mg + placebo | Yuhan | Phase 2 | 52 |
| E3810 + E3810 + Placebo | Eisai | Phase 3 | 77 |
| RABEPRAZOLE SODIUM + RABEPRAZOLE SODIUM | Eisai | Phase 3 | 77 |
| Teprenone capsule and placebo of sucralfate + Sucralfate and placebo of teprenone | Eisai | Approved | 85 |
| ABT-981 + Placebo for ABT-981 | AbbVie | Phase 2 | 52 |
| Omeprazole | AstraZeneca | Phase 3 | 77 |
| Esomeprazole + Lansoprazole | AstraZeneca | Approved | 85 |
| Nexium 20mg + Nexium 10mg | AstraZeneca | Phase 3 | 77 |
| Omeprazole | AstraZeneca | Phase 3 | 77 |
| AZD0865 | AstraZeneca | Phase 2 | 52 |
| Esomeprazole + Lansoprazole | AstraZeneca | Approved | 85 |
| Esomeprazole + Esomeprazole | AstraZeneca | Approved | 85 |
| AZD0865 | AstraZeneca | Phase 2 | 52 |
| Alendronate Effervescent Oral Tablet | Amgen | Phase 2 | 51 |
| Omeprazole/sodium bicarbonate | Bausch Health | Approved | 80 |
| Vonoprazan | Phathom Pharmaceuticals | Phase 1 | 28 |
| Vonoprazan + Lansoprazole | Phathom Pharmaceuticals | Phase 3 | 72 |
| Vonoprazan + Placebo | Phathom Pharmaceuticals | Phase 2 | 47 |
| Vonoprazan | Phathom Pharmaceuticals | Pre-clinical | 18 |
| Vonoprazan + Placebo | Phathom Pharmaceuticals | Phase 3 | 72 |